ArticleLeukemia2017
Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML.
Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Myeloid neoplasm occurrence during stable molecular remission of NPM1-mutated AML: are we facing secondary disease or AML relapse?Blood cancer journal · 2023Article
- NPM 1 Mutations in AML-The Landscape in 2023.Cancers · 2023Review
- Investigation of measurable residual disease in acute myeloid leukemia by DNA methylation patterns.Leukemia · 2022Article
- Article
- Review
- Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia.Blood · 2020Review
- Molecular characterization of a second myeloid neoplasm developing after treatment for acute myeloid leukemia.Leukemia · 2020Article
- The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML.American journal of hematology · 2019Article
- Evolutionary trajectory of leukemic clones and its clinical implications.Haematologica · 2019Review
- Article
- Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia.Leukemia · 2018Article
- Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia.Blood advances · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
28690314What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.